Corvus Pharmaceuticals, Inc. (CRVS)

2,0800 +0,0500 (+2,46%) Alla chiusura: 04:00PM EDT

Corvus Pharmaceuticals, Inc.

863 Mitten Road
Suite 102
Burlingame, CA 94010
United States
650 900 4520
https://www.corvuspharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 28

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Richard A. Miller M.D.	Co-Founder, President, CEO & Chairman of the Board	116,31k	N/D	1951
Dr. Peter A. Thompson FACP, M.D.	Co-Founder & Independent Director	47k	N/D	1960
Mr. Leiv Lea	Chief Financial Officer	400,21k	N/D	1954
Dr. William Benton Jones Ph.D.	Senior Vice President of Pharmaceutical Development	355,7k	N/D	1966
Dr. James T. Rosenbaum M.D.	Senior Vice President of Research	N/D	N/D	N/D
Mr. Jeffrey S. Arcara	Chief Business Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Governance aziendale

L'ISS Governance QualityScore di Corvus Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.